文献速递慢性静脉疾病

黑人或非裔美国患者因晚期静脉疾病接受大隐静脉消融术且术后症状改善最少

Black or African American patients undergo great saphenous vein ablation procedures for advanced venous disease and have the least improvement in their symptoms after these procedures.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2023-06-19

该回顾性分析利用2014至2020年血管质量倡议数据,纳入9009例因症状性慢性静脉功能不全接受大隐静脉腔内消融的患者,按种族分层比较临床分期与术后改善。黑人或非裔美国患者就诊时临床分期更晚,术后静脉临床严重程度评分和患者报告结局的平均改善低于白人和西班牙裔患者。

要点

  • 黑人或非裔美国患者就诊时慢性静脉功能不全临床分期较白人和西班牙裔更晚。
  • 黑人或非裔美国患者术后静脉临床严重程度评分平均改善3.25±4.4,低于白人4.25±4.13和西班牙裔4.42±3.78。
  • 西班牙裔人群更年轻,但白人和西班牙裔患者对治疗的反应相似。

核心结论

  • 不同种族间慢性静脉功能不全的临床严重程度和症状表现存在差异。
  • 黑人或非裔美国患者就诊时慢性静脉功能不全较白人和西班牙裔患者更晚。
  • 术后分析显示黑人或非裔美国患者慢性静脉功能不全的临床和自报改善较差。
  • 尽管西班牙裔人群更年轻,白人和西班牙裔患者对治疗的反应相似。

研究设计与样本

  • 回顾性分析2014至2020年血管质量倡议数据中所有因症状性慢性静脉功能不全接受大隐静脉腔内消融(射频或激光)的患者。
  • 共纳入9009例患者,平均年龄分布56岁,女性6041例(67.1%)。
  • 按患者种族分层分析患者特征和结局,使用χ2检验和Kruskal-Wallis equality-of-populations秩检验测量研究结局。

主要发现

  • 9009例患者中白人7892例(87.6%)、西班牙裔627例(6.9%)、黑人或非裔美国490例(18.3%)。
  • 临床分期C3:黑人或非裔美国32.9%、西班牙裔38.9%、白人46%;C5:黑人或非裔美国4.7%、西班牙裔2.1%、白人2.3%;C6:黑人或非裔美国12.7%、西班牙裔3.2%、白人6.2%。
  • 黑人或非裔美国患者更可能超重或肥胖(66%;P < .001),术前更少服用抗凝药物(11%;P < .001)。
  • 非白人种族与在医院环境中治疗的概率更高相关(黑人或非裔美国63.6%;西班牙裔87.5%;P < .001)。
  • 术后静脉临床严重程度评分和患者报告结局的平均改善:黑人或非裔美国3.25±4.4(P < .001),低于白人4.25±4.13(P < .001)和西班牙裔4.42±3.78(P < .001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Chronic venous insufficiency is an increasingly prevalent problem in the United States, with >25 million individuals currently affected. Previous work has shown that racial minorities and low socioeconomic status are associated with a worse clinical presentation and response to treatment. The present study aimed to determine the relationship between race, patient variables, hospital outcomes, and response to treatment for patients presenting for chronic venous insufficiency intervention. METHODS: We performed a retrospective analysis of all patients who underwent endovenous ablation (radiofrequency or laser) of the great saphenous vein to treat symptomatic, chronic venous insufficiency using Vascular Quality Initiative data from 2014 to 2020. Patient characteristics and outcomes were analyzed stratified by patient race. The χ2 test and the Kruskal-Wallis equality-of-populations rank test were used to measure the study outcomes. The primary outcomes were an improved venous clinical severity score and improvement in patient-reported outcomes. Patient characteristics, CEAP (clinical, etiologic, anatomic, pathophysiologic) classification, prior venous interventions, length of stay, and time to follow-up were compared between races. RESULTS: The database consisted of 9009 predominantly female patients (n = 6041; 67.1%), with a mean age distribution of 56 years. Of the 9009 patients, 7892 are White (87.6%), 627 Hispanic (6.9%), and 490 Black or African American (18.3%). The Hispanic cohort was younger than their White and Black/African American counterparts. Black/African American patients presented with more advanced clinical stages than did the White and Hispanic groups. The clinical stage according to race was as follows: C3-Black/African American, 32.9%; Hispanic, 38.9%; White, 46%; C5-Black/African American, 4.7%; Hispanic, 2.1%; White, 2.3%; and C6-Black/African American, 12.7%; Hispanic, 3.2%; White, 6.2%. Black/African American patients were more likely to present as overweight or obese (66%; P < .001) and less likely to be taking anticoagulation medication preoperatively (11%; P < .001). Non-White race was associated with a higher probability of treatment in the hospital setting (Black/African American, 63.6%; Hispanic, 87.5%; P < .001). Black/African American patients (3.25 ± 4.4; P < .001) demonstrated lower mean improvement postoperatively in both the venous clinical severity score and patient-reported outcomes than their White (4.25 ± 4.13, P <.001) and Hispanic (4.42 ± 3.78; P < .001) counterparts. CONCLUSIONS: Differences exist in the clinical severity and symptom presentation based on race. Black/African American patients present with more advanced chronic venous insufficiency than do their White and Hispanic counterparts. Furthermore, the postprocedural analysis showed inferior clinical and self-reported improvement in chronic venous insufficiency for the Black/African American patients. Although the Hispanic population was younger, the White and Hispanic patients experienced similar responses to treatment.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Zil-E-Ali A, DeHaven C, Alamarie B, et al. Black or African American patients undergo great saphenous vein ablation procedures for advanced venous disease and have the least improvement in their symptoms after these procedures. J Vasc Surg Venous Lymphat Disord. 2023. PMID: 37343786. doi:10.1016/j.jvsv.2023.06.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。